Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| ALX Oncology Holdings Inc. | Evorpacept w/ cetuximab and pembrolizumab | Colorectal cancer | Phase 2 | Data Released | Intravenous | Oncology |
| ALX Oncology Holdings Inc. | ALX148 + HERCEPTIN (Trastuzumab) + CYRAMZA (ramucirumab) and TAXOL (paclitaxel) - (ASPEN-06) | 2nd line or greater gastric/gastroesophageal junction cancer | Phase 2/3 | Data Released | Intravenous | Oncology |
| ALX Oncology Holdings Inc. | Evorpacept w/ liposomal doxorubicin and pembrolizumab | Platinum-resistant ovarian cancer (PROC) | Phase 2 | Ongoing | Intravenous | Oncology |
| ALX Oncology Holdings Inc. | ALX148 and KEYTRUDA (pembrolizumab) - (ASPEN-03) | Head and neck squamous cell carcinoma (HNSCC) | Phase 2 | Trial Discontinued | Intravenous | Oncology |
| ALX Oncology Holdings Inc. | Evorpacept + trastuzumab - (ASPEN-09-Breast) | HER2-positive metastatic breast cancer | Phase 2 | Enrollment Initiation | Intravenous | Oncology |
| ALX Oncology Holdings Inc. | Evorpacept in combination KEYTRUDA (pembrolizumab) - (IST trial) | Human papillomavirus-mediated oropharyngeal cancer (HPVOC) | Phase 2 | Enrollment Initiation | Intravenous | Oncology |
| ALX Oncology Holdings Inc. | ALX148 and KEYTRUDA (pembrolizumab) - (ASPEN-04) | Head and Neck Squamous Cell Carcinoma | Phase 2 | Data Released | Intravenous | Oncology |
| Alzamend Neuro Inc. | AL001 | Dementia related to Alzheimer's | Phase 2a | Study May Proceed Letter | oral | Neurology |
